Daiichi Sankyo Co Ltd

Company Profile

• Business description

  Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.

• Contact

  3-5-1, Nihonbashi-Honcho
  Chuo-ku
  Tokyo103-8426
  JPN

  T: +81 362251111

  https://www.daiichisankyo.co.jp

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Drug Manufacturers - General

  Fiscal Year End

  31 March 2027

  Employees

  20,171